

1 *Title Page*

2
3 **Interpretation of non-responders to SARS-CoV-2 vaccines using WHO International**
4 **Standard**

5
6 Qiang Zeng, MD^{1*}, Xue Yang, MD^{2*}, Qi Gao, PhD³, Biao-yang Lin, PhD⁴, Yong-zhe Li, MD⁵,
7 Gang Huang, MD^{6†} and Yang Xu, MD, PhD^{4,6 †}

8 ¹Health Management Institute, the Second Medical Center & National Clinical Research Center
9 for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China

10 ²Outpatient Department, the Second Medical Center & National Clinical Research Center for
11 Geriatric Diseases, Chinese PLA General Hospital, Beijing, China

12 ³Beijing Hotgen Biotechnology Inc., Beijing, China

13 ⁴Zhejiang University, Hangzhou, China

14 ⁵Department of Laboratory Medicine, Peking Union Medical College Hospital, Beijing, China

15 ⁶Laboratory of Special Diagnosis & Shanghai Key Laboratory of Molecular Imaging, Shanghai
16 University of Medicine and Health Sciences, Shanghai, China

17 ***These authors contributed equally to the study.**

18 **†Correspondence:** Gang Huang, MD; Yang Xu, MD, PhD, yxu1627@126.com

19
20
21
22
23
24 **Keyword: COVID-19; vaccine; non-responders; WHO; international standard; CD4 cells;**
25 **CD8 cells; B cells; BAU/mL; IU/mL**

27 **ABSTRACT**

28 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic
29 with more than 485 millions infected. Questions about non-responders to SARS-CoV-2 vaccines
30 remain unaddressed. Here, we report data from people after administering the complete dose of
31 SARS-CoV-2 vaccines using the World Health Organization International Standard for anti-
32 SARS-CoV-2 immunoglobulin. Our study showed that immune cells such as CD4 cells, CD8
33 cells, and B cells and anti-spike immunoglobulin G levels were significantly reduced in the
34 elderly. There were 7.5% non-responders among the 18–59 yr group and 11.7% in the ≥ 60 yr
35 group. A titer of anti-SARS-CoV-2 spike immunoglobulin G is below 50 BAU/mL to be
36 considered as non-responders at intervals of 30 to 90 days after the last vaccine dose. Booster
37 vaccination may be recommended for non-responders to reduce the disease severity and
38 mortality.

39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57

58 **INTRODCTION**

59

60 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic,
61 infecting more than 485 million people and killing more than 6 million.¹ Since December 2020
62 the World Health Organization (WHO) recommends vaccination against COVID-19, nine types
63 of coronavirus disease 2019 (COVID-19) vaccines have been included in the emergency use
64 list.²

65

66 Vaccination against COVID-19 is especially important in reducing severe illness and mortality.
67 According to the data of the Centers for Disease Control and Prevention (CDC) in 2016-2017,
68 the mortality rate caused by influenza virus was 0.13%.³

69

70 In order to bring the COVID-19 pandemic under control as soon as possible and ensure that the
71 mortality rate of COVID-19 is close to that caused by influenza virus, the prevention and
72 treatment of children as well as elderly and immunocompromised people has emerged as a top
73 priority at present.⁴⁻⁸ Sun et al. first reported that hospitalization and severe outcomes were
74 similar in unvaccinated healthy individuals and immunocompromised patients who received full
75 SARS-CoV-2 vaccination in the United States, suggesting that COVID-19 breakthrough
76 infection after SARS-CoV-2 vaccination is associated with immune dysfunction. Hospitalization
77 and severe outcomes were 21.1% and 1.9%, respectively, in unvaccinated healthy individuals,
78 and 20.7% and 2.1%, respectively, in patients with immune dysfunction after 14 days following
79 full vaccination, indicating that an immune barrier is not well established in
80 immunocompromised patients after full vaccination and post-vaccination testing is necessary to
81 identify immunocompromised individuals without specific immunity so they can be given
82 additional prophylaxis after full vaccination.⁸ This study suggests that post-vaccination testing
83 will help reduce mortality, showing the importance and urgency of post-vaccination assessments
84 using an international standard.

85

86 To date, more than 5 billion people have been vaccinated against COVID-19.⁹ In clinical trials
87 associated with COVID-19 vaccines, the effective COVID-19 vaccination reportedly elicits
88 specific antibody responses. An effective humoral immune response is defined as a ≥ 4 -fold

89 increase in antibody titers from baseline within 1–3 months of the vaccination procedure and is
90 considered gold standard for assessing antibody protection in vaccinated recipients.¹⁰⁻¹² In
91 contrast, a non-responder is an individual who demonstrates no effective humoral immune
92 response despite the completion of the suggested vaccination procedure.¹³⁻¹⁴

93 During the promotion of vaccination, several factors affecting the response to the COVID-19
94 vaccines were taken into consideration, especially the reduced response to the COVID-19
95 vaccine in children, elderly people, and immunocompromised population. However, despite the
96 completion of COVID-19 vaccination in the population as per the recommendations by WHO,
97 the outcomes concerning the protective levels of antibody concentration and factors determining
98 the identification of non-responders still remain inconclusive.¹⁵⁻²⁵

99
100 To this end, in December 2020, WHO issued an international standard (IS) for the quantification
101 of anti-SARS-CoV-2 immunoglobulin for post-vaccination testing.²⁶⁻²⁷ This standard provides a
102 unified benchmark for effective antibody protective concentrations after vaccination. In this
103 clinical study, we analyzed 627 people that volunteered to participate in COVID-19 vaccination
104 and subsequent assessment of antibody titers. After two doses of vaccination, the antibody titer
105 was evidently increased by ≥ 4 times from baseline as the gold standard. Furthermore, the data
106 using the WHO IS was comprehensively analyzed to provide insights for improving the efficacy
107 of vaccines, help in reduction of breakthrough infections after vaccines, and ultimately to reduce
108 the disease severity and mortality.

109

110 **RESULTS**

111 **Immune characteristics of 627 cases prior to vaccination**

112 There were 42.4% (266/627) individuals aged ≥ 60 yr and 50.9% (319/627) male enrolled in the
113 study (Table 1). In the 18–59 yr group, the medians [interquartile ranges (IQRs)] of ALC, CD4
114 cell count, CD8 cell count, B cell count, and NK cell count were 1,476 (1,168–1,875), 851 (677–
115 1,151), 490 (357–632), 256 (179–367), and 193 (141–287)/mm³, respectively. On the contrary, in
116 the ≥ 60 yr group, the respective medians (IQRs) were 1,281 (1,023–1,520), 747 (562–955), 418
117 (288–544), 204 (138–303), and 234 (162–355)/mm³ (Table 1). In fact, the number of naïve
118 lymphocytes, CD4 cells, CD8 cells, and B cells were significantly reduced in the elderly

119 population than that in the 18–59 yr population ($P < 0.001$). Hence, these naïve immune cells
120 wane significantly, while the NK cell counts increase significantly in the elderly people (Table 1,
121 Fig. 1A).

122

123 **Anti-spike IgG levels in the 627 cases after complete vaccination**

124 We analyzed the anti-spike immunoglobulin (Ig)G levels after complete vaccination of the 627
125 cases (Table 1). Post-vaccination testing was done at intervals of 14 to 90 days after the second
126 vaccine dose. The anti-spike IgG seropositive rates were 99.7% in the 18–59 yr population and
127 98.9% in the ≥ 60 yr population based on the cutoff (Table 1). However, the quantitative level of
128 the anti-spike IgG was significantly lower in the ≥ 60 yr group (median 307.2, IQRs 118.2–417.3
129 BAU/mL) than that in the 18–59 yr group (median 416.8, IQRs 355.7–479.2 BAU/mL) (Table 1,
130 Fig. 1B). The reference ranges (2.5–97.5 percentile) were 88.6–576.2 BAU/mL in the 18–59 yr
131 group and 27.7–491.0 BAU/mL in the ≥ 60 yr group at 14–90 days after complete vaccination
132 (Table 2).

133

134 **Characteristics of seroconversion after the complete dose**

135 Thereafter, we evaluated the vaccine-induced responses, based on the post-second-dose and pre-
136 second-dose titers, using the 4-fold increase parameter (fold-index < 4 or ≥ 4) (Table 2).
137 Remarkably, there were 7.5% non-responders (fold-index < 4) among the 18–59 yr group and
138 11.7% in the ≥ 60 yr group (Table 2, Fig. 1C), indicating that the positive rate of anti-spike IgG
139 cannot represent the seroconversion rate. Therefore, the anti-spike IgG positivity or
140 seroprevalence might not be a suitable predictor of seroconversion (fold-index ≥ 4).

141

142 In the 18–59 yr group, the median (IQRs) levels of anti-spike IgG and the reference ranges were
143 115.8 (88.6–167.8) and 18.3–266.3 BAU/mL with fold-index < 4 , respectively and 420.8 (369.9–
144 480.6) and 200.7–576.5 BAU/mL with fold-index ≥ 4 , respectively ($P < 0.0001$). In contrast, in
145 the ≥ 60 yr group, the median (IQRs) levels of anti-spike IgG and the reference ranges were 63.9
146 (35.1–106.9) and 5.4–317.8 BAU/mL with fold-index < 4 , respectively and 346.0 (160.4–424.7)
147 and 46.6–491.1 BAU/mL with fold-index ≥ 4 , respectively ($P < 0.0001$). The reference ranges
148 (1–99 percentile) for responders (fold-index ≥ 4) were 43.9–592.0 BAU/mL in combination of
149 the 18–59 yr group and the ≥ 60 yr group at 14–90 days after complete vaccination (Figure 1C).

150
151 We further observed that the seroconversion rate was significantly related to the proportion of
152 certain naïve immune cells (Table 2). Particularly, the lymphocyte count was significantly
153 different ($P < 0.0001$) between the fold-index <4 or ≥ 4 groups. For instance, in the 18–59 yr
154 group, the lymphocyte count was $1,130/\text{mm}^3$ [95% CI (1,007–1,252)/ mm^3] in the <4 group and
155 $1,578/\text{mm}^3$ [95% CI (1,524–1,633)/ mm^3] in the ≥ 4 group. On the contrary, in the ≥ 60 yr group,
156 the lymphocyte count was $1,015/\text{mm}^3$ [95% CI (888–1,143)/ mm^3] in the <4 group and
157 $1,344/\text{mm}^3$ [95% CI 1,291–1,397)/ mm^3] in the ≥ 4 group. Similarly, the CD4 cell counts were
158 significantly different ($P < 0.0001$) between the individuals with fold-index <4 and ≥ 4 . For
159 instance, in the 18–59 yr population, the CD4 cell count was $631/\text{mm}^3$ [95% CI (555–708)/ mm^3]
160 versus $942/\text{mm}^3$ [95% CI (905–979)/ mm^3] in the <4 and ≥ 4 groups, respectively, while in the
161 ≥ 60 yr age group, it was $563/\text{mm}^3$ [95% CI (494–631)/ mm^3] versus $818/\text{mm}^3$ [95% CI (777–
162 858)/ mm^3] in the <4 and ≥ 4 groups, respectively. With respect to the B cell count, there was a
163 significant difference ($P < 0.0001$) between the individuals with fold-index < 4 and ≥ 4 . For
164 example, in the 18–59 age group, the B cell count was $119/\text{mm}^3$ [95% CI (72–166)/ mm^3] versus
165 $306/\text{mm}^3$ [95% CI (289–323)/ mm^3] in the <4 and ≥ 4 groups, respectively, whereas in the ≥ 60 yr
166 age group, it was $74/\text{mm}^3$ [95% CI (60–88) / mm^3] versus $248/\text{mm}^3$ [95% CI (231–266)/ mm^3] in
167 the <4 and ≥ 4 groups, respectively. Regarding the CD8 cell count, a significant difference was
168 noted only between the individuals with <4 and ≥ 4 fold-indices in the 18–59 yr age group
169 [$414/\text{mm}^3$ (95% CI 349–479/ mm^3) versus $532/\text{mm}^3$ (95% CI 508–557/ mm^3), $P = 0.0081$].
170 However, the CD8 cell count in the ≥ 60 yr group and NK cell count in both the age groups did
171 not portray any significant differences.

172
173 **DISCUSSION**

174
175 To the best of our knowledge, this is the first clinical study to report non-responders after
176 administering the complete dose of inactivated SARS-CoV-2 vaccines using WHO International
177 Standard (IS) for anti-SARS-CoV-2 immunoglobulin (Ig). Whether there is a humoral immune
178 response following COVID-19 vaccination is a marker of population immunity.²⁸⁻³⁰ Typically,
179 effective humoral immune response is defined as a ≥ 4 -fold rise in antibody titers from baseline
180 within 1-3 months of the vaccination schedule. The use of anti-SARS-CoV-2 assays with the

181 WHO IS can facilitate the comparison of the strength of the humoral immune response between
182 individuals, making the data more accurate and providing reliable data for the COVID-19
183 vaccine booster. Therefore, adequate clinical trials are necessary regarding the assessment of
184 immune characteristics of individuals prior to vaccine booster shot, such that the mortality in the
185 pandemic may be quickly reduced.

186
187 We used an anti-SARS-CoV-2 spike quantitative IgG kit (COVID-SeroKlir Kantaro SARS-CoV-
188 2 IgG Ab Kit) approved by the Food and Drug Administration (FDA) under Emergency Use
189 Authorization (EUA) with the WHO IS. This kit has been extensively evaluated in many clinical
190 studies, including neutralizing antibodies after SARS-CoV-2 infection, immunological memory
191 to SARS-CoV-2, convalescent plasma treatment of severe COVID-19, and antibody responses to
192 mRNA vaccines in healthy people and patients.³⁰⁻³⁵ After complete two dose vaccination, the
193 reference ranges (1–99 percentile) for all responders (fold-index ≥ 4) were 43.9–592.0 BAU/mL.
194 A preliminary cutoff of 50 BAU/mL was set based on percentiles of all responders and
195 convenience of manufacturing standard controls. The final cutoff value will be determined by
196 future clinical trials.

197
198 The WHO IS has demonstrated to be enabled to comparison between different types of vaccines.
199 Zitt et al. reported that the median titers of non-seroconversion and seroconversion were 635.5
200 and 1,565.0 BAU/mL after two doses of mRNA vaccination in hemodialysis patients at $67.6 \pm$
201 14.8 years, respectively;³⁶ whereas we reported that the median titers of non-seroconversion and
202 seroconversion were 63.9 and 346.0 BAU/mL after giving two doses of inactivated SARS-CoV-2
203 vaccines at 67 ± 6 years, respectively, indicating that the mRNA vaccines is more potent than the
204 inactivated SARS-CoV-2 vaccines.³⁷

205
206 The benefits of post-vaccination serologic testing outweigh the potential risks. Zitt et al. reported
207 there were median titer of 1,440 BAU/mL in documented hepatitis B virus (HBV) vaccine
208 responders (anti-HBs antibody ≥ 10 mIU/mL) and median titer of 308.5 BAU/mL in non-
209 responders after two doses of mRNA vaccination ($P = 0.035$), suggesting that post-vaccination
210 testing might predict the general immune competence.³⁶ All anti-SARS-CoV-2 spike IgG-
211 positive patients recovered from the infection respond well to the vaccine, which indirectly

212 proves this phenomenon.²⁹⁻³⁰ If this theory turns out to be correct, then it is possible that SARS-
213 CoV-2 vaccine responders have a strong ability to produce antibodies against variants through
214 asymptomatic infections. This may support the Government-issued "immunity passports" to
215 demonstrate an individual's immune ability according to the WHO IS (≥ 50 BAU/mL) after
216 recovered from COVID-19 or SARS-CoV-2 vaccination.

217
218 The most significant benefit of post-vaccination serologic testing is to save patient lives. Chukwu
219 et al. reported clinical findings in a group of kidney transplant recipients vaccinated with 2 doses
220 of vaccines (72% of BNT162b2, 28% of AZD1222). There were 22 breakthrough infections and
221 3 deaths after vaccination, including 77% (17/22) infections and 13.6% (3/22) deaths in the
222 seronegative group and only 23% (5/22) infections and 0% (0/22) deaths in the seropositive
223 group.³⁸ However, this study did not use the WHO IS to get a cutoff for the responder. Therefore,
224 there may be some non-responders (fold-index <4) in the seropositive group according to our
225 study.

226
227 For SARS-CoV-2 vaccine non-responders, one benefit from post-vaccination serologic testing to
228 the patient is to get a booster shot as soon as possible.³⁹⁻⁴⁰ For persistent non-responders to
229 SARS-CoV-2 vaccination, anti-SARS-CoV-2 antibody injections could save these lives in the
230 seronegative group after the vaccination.⁴¹⁻⁴³

231
232 Another good example for post-vaccination serologic testing is the HBV vaccine. After the first
233 hepatitis B vaccine was approved in the United States in 1981 and the recombinant hepatitis B
234 vaccine developed by Maurice Hilleman was approved by the FDA in 1986, it took scientists
235 more than 20 years to realize that the vaccine did not provide good protection for the elderly and
236 certain immunocompromised populations and put them at risk of breakthrough infections after
237 vaccination.⁴⁴⁻⁴⁵ Szmunn et al. have first reported that 7.4% of immunized individuals fail to
238 elicit detectable specific antibodies after two doses of hepatitis B vaccine, suggesting that there
239 are non-responders in the population in 1982.⁴⁶ Roome et al. have found in 1993 that 11.9% of
240 individuals with hepatitis B vaccine were no or inadequate levels of antibody, suggesting that
241 post-vaccination testing should be done at intervals of 30 to 90 days after the last vaccine dose.⁴⁷
242 Many subsequent studies have shown that the elderly and immunocompromised populations are

243 associated with reduced vaccine responses to hepatitis B vaccination.⁴⁵⁻⁴⁷ The CDC has
244 recommended post-vaccination serologic testing using the WHO IS for immunocompromised
245 individuals following HBV vaccination.⁴⁵ For persistent non-responders (anti-HBs antibody <10
246 mIU/mL, the WHO IS 07/164) to HBV vaccination, anti-HBV Ig injections are recommended if
247 exposed to HBV.⁴⁵

248
249 Furthermore, the lower immune cell count may form the major risk factor for non-responders
250 after administration of full SARS-CoV-2 vaccine in our study. Van Oekelen et al. have
251 demonstrated that 32.3% (10/31) of multiple myeloma patients with severe lymphopenia
252 (<500/mm³) remained negative for SARS-CoV-2 spike IgG after two doses of mRNA vaccines
253 (OR 2.89, 95% CI 1.10–7.20, *P* = 0.018).⁴⁸ Similarly, two studies reported that 63.7–77.3% of
254 patients who had a history of anti-CD20 therapy for B cell depletion remained negative for
255 SARS-CoV-2 IgG after receiving mRNA vaccines, suggesting that B cells are required for
256 humoral immunity following COVID-19 vaccines.⁴⁹⁻⁵⁰ Hence, further clinical trials must be
257 performed to finalize effective booster shots for immunocompromised people after administering
258 the complete dose in the general population.⁵¹⁻⁵⁵

259
260 According to this study, the anti-spike IgG seropositivities were 99.7% and 98.9% in the 18–59
261 yr and ≥60 yr groups, respectively. Additionally, certain naïve immune cells, such as CD4 cells,
262 CD8 cells, and B cells exhibited significant waning in the elderly people, suggesting that the
263 non-seroconversion rates were higher in individuals with lower immune cell counts. Incidentally,
264 the anti-spike IgG seroprevalence or positivity was inconsistent with seroconversion rates
265 observed in our study, thereby suggesting that anti-spike IgG positivity might not be a suitable
266 predictor for the seroconversion rates. Our data showed that 7.5-11.7% of non-responders existed
267 in the population, even some non-responders with anti-spike IgG positivity, supporting the
268 CDC's concern that some non-responders are positive for anti-spike IgG after vaccination.⁵⁶ An
269 FDA EUA quantitative assay with the WHO IS (20/136) may help to address this issue.²⁶⁻²⁷

270
271 There are several potential strategies that can be employed to reduce the COVID-19 mortality
272 rate below 0.13 % of that caused by influenza virus. These include the following measures: (1)
273 Increase the vaccination rate of the population;² (2) Develop vaccines against emerging and

274 potential variants;⁵⁷⁻⁶² (3) Administer booster vaccines for non-responders;⁶³⁻⁶⁵ (4) Assessment of
275 humoral immune response of children, the elderly, and immunocompromised persons within 1–3
276 months after 4th dose;^{45, 65-70} and (5) Incorporate additional protective measures for individuals
277 with persistent (4th or 5th dose) negative humoral immune response after booster vaccination,
278 such as injection of anti-SARS-CoV-2 immunoglobulins, antiviral drug treatment, usage of N95
279 masks in endemic areas, etc.^{41-43, 71-74}

280

281 CONCLUSIONS

282 Immune cells such as CD4 cells, CD8 cells, and B cells and anti-spike IgG levels were
283 significantly reduced in the elderly. There were 7.5% non-responders among the 18–59 yr group
284 and 11.7% in the ≥ 60 yr group. A titer of anti-SARS-CoV-2 spike IgG is below 50 BAU/mL to be
285 considered as non-responders at intervals of 30 to 90 days after the last vaccine dose. Booster
286 vaccination may be recommended for non-responders to reduce the disease severity and
287 mortality.

288

289 ACKNOWLEDGMENTS

290

291 **Limitations:** Study limitations include small sample size, data was only sourced from a single
292 center, and lack of RBD/spike-specific cellular immune assessments.

293

294 **Funding:** This work was supported by the project of “**Antibody Immunity Evaluation after**
295 **SARS-CoV-2 Vaccination in General Population**” (Z211100002521024) from Beijing Science
296 and Technology Commission.

297

298 **Author Contributions:** Drs Zeng and Xu had full access to all of the data in the study and take
299 responsibility for the integrity of the data and the accuracy of the data analysis. Drs Zeng and
300 Yang served as co–first authors and contributed equally to the work. Concept and design: All
301 authors. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript:
302 Zeng and Xu. Critical revision of the manuscript for important intellectual content: Zeng, Huang
303 and Xu. Statistical analysis: Zeng, Huang and Xu. Obtained funding: Zeng and Gao.
304 Administrative, technical, or material support: Zeng, Yang, Lin, Xu. Supervision: Zeng and Xu.

305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335

Institutional Review Board Statement: The study was approved by the institutional ethics committee (No. S2021-481-01).

Informed Consent Statement: All study participants provided their informed written consent.

Competing interests: None.

Data and materials availability: All data are available in the manuscript or the supplementary materials.

336 REFERENCES

- 337 1. World Health Organization. WHO coronavirus (COVID-19) dashboard. <https://covid19.who.int/>
- 338 2. World Health Organization. COVID-19 advice for the public: Getting vaccinated.
339 <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice>
- 340 3. Centers for Disease Control and Prevention. Burden estimates for the 2016-2017 influenza season.
341 <https://www.cdc.gov/flu/about/burden/2016-2017.html>
- 342 4. Marks KJ, Whitaker M, Anglin O et al. Hospitalizations of children and adolescents with laboratory-confirmed
343 COVID-19 — COVID-NET, 14 States, July 2021–January 2022. *Morbidity and Mortality Weekly Report (MMWR)*.
344 2022;71(7):271–278.
- 345 5. Tenforde MW, Self WH, Adams K et al. Association between mRNA vaccination and COVID-19 hospitalization
346 and disease severity. *JAMA*. 2021;326, 2043–2054. doi: 10.1001/jama.2021.19499.
- 347 6. Zeng Q, Li YZ, Dong SY et al. Dynamic SARS-CoV-2-specific immunity in critically ill patients with
348 hypertension. *Front Immunol*. 2020;11, 596684. doi: 10.3389/fimmu.2020.596684.
- 349 7. Lipsitch M, Krammer F, Regev-Yochay G et al. SARS-CoV-2 breakthrough infections in vaccinated individuals:
350 measurement, causes and impact. *Nat. Rev. Immunol*. 2022;22:57–65. doi: 10.1038/s41577-021-00662-4.
- 351 8. Sun J, Zheng Q, Madhira V et al. Association between immune dysfunction and COVID-19 breakthrough
352 infection after SARS-CoV-2 vaccination in the US. *JAMA Intern. Med*. 2022;182:153–162. doi:
353 10.1001/jamainternmed.2021.7024.
- 354 9. Johns Hopkins University & Medicine. Understanding vaccination progress.
355 <https://coronavirus.jhu.edu/vaccines/international>
- 356 10. Xia SL, Zhang YT, Wang YX et al. Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-
357 CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial. *Lancet Infect Dis*
358 2022; 22: 196–208. DOI:[https://doi.org/10.1016/S1473-3099\(21\)00462-X](https://doi.org/10.1016/S1473-3099(21)00462-X).
- 359 11. Xia S, Duan K, Zhang Y et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and
360 immunogenicity outcomes: interim analysis of 2 randomized clinical trials. *JAMA*. 2020 Sep 8;324(10):951-960.
361 doi: 10.1001/jama.2020.15543.
- 362 12. Long QX, Liu BZ, Deng HJ et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med*.
363 2020;26(6):845-848. doi: 10.1038/s41591-020-0897-1.
- 364 13. Weissman JY, Tsuchiyose MM, Tong MJ et al. Lack of response to recombinant hepatitis B vaccine in
365 nonresponders to the plasma vaccine. *JAMA*. 1988;260(12):1734-1738.
- 366 14. Simon D, Tascilar K, Fagni F et al. Efficacy and safety of SARS-CoV-2 revaccination in non-responders with
367 immune-mediated inflammatory disease. *Ann Rheum Dis*. 2021;annrheumdis-2021-221554. doi:
368 10.1136/annrheumdis-2021-221554.
- 369 15. Atmar RL, Lyke KE, Deming ME et al. Homologous and heterologous Covid-19 booster vaccinations. *N Engl J*
370 *Med*. 2022 Mar 17;386(11):1046-1057. doi: 10.1056/NEJMoa2116414.
- 371 16. Polack FP, Thomas SJ, Kitchin N et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J*
372 *Med*. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577.
- 373 17. Wu K, Werner AP, Koch M et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. *N Engl J Med*.
374 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179.
- 375 18. Benenson S, Oster Y, Cohen MJ et al. BNT162b2 mRNA Covid-19 vaccine effectiveness among health care
376 workers. *N Engl J Med*. 2021 May 6;384(18):1775-1777. doi: 10.1056/NEJMc2101951.
- 377 19. Dagan N, Barda N, Kepten E et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination
378 setting. *N Engl J Med*. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765.
- 379 20. Baden LR, El Sahly HM, Essink B et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J*
380 *Med*. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389.
- 381 21. Wu K, Werner AP, Koch M et al. Serum neutralizing activity elicited by mRNA-1273 vaccine. *N Engl J Med*.
382 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179.
- 383 22. Boyarsky BJ, Werbel WA, Avery RK et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in
384 solid organ transplant recipients. *JAMA*. 2021;325(21):2204-2206. doi: 10.1001/jama.2021.7489.
- 385 23. Goldshtein I, Nevo D, Steinberg DM et al. Association between BNT162b2 vaccination and incidence of SARS-
386 CoV-2 infection in pregnant women. *JAMA*. 2021;326(8):728-735. doi: 10.1001/jama.2021.11035.
- 387 24. Logunov DY, Dolzhikova IV, Shcheblyakov DV et al. Safety and efficacy of an rAd26 and rAd5 vector-based
388 heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
389 *Lancet*. 2021;397(10275):671-681. doi: 10.1016/S0140-6736(21)00234-8.
- 390 25. Al Kaabi N, Zhang Y, Xia S et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19

- 391 infection in adults: A randomized clinical trial. *JAMA*. 2021;326(1):35-45. doi: 10.1001/jama.2021.8565.
- 392 26. Kristiansen PA, Page M, Bernasconi V et al. WHO International Standard for anti-SARS-CoV-2
393 immunoglobulin. *Lancet* 2021;397:1347-1348. doi:10.1016/S0140-6736(21)00527-4.
- 394 27. Knezevic I, Mattiuzzo G, Page M et al. WHO International Standard for evaluation of the antibody response to
395 COVID-19 vaccines: call for urgent action by the scientific community. *Lancet Microbe* 2022;3: e235–40. doi:
396 10.1016/S2666-5247(21)00266-4.
- 397 28. Khoury DS, Cromer D, Reynaldi A et al. Neutralizing antibody levels are highly predictive of immune protection
398 from symptomatic SARS-CoV-2 infection. *Nat Med*. 2021;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8.
- 399 29. Saadat S, Rikhtegaran Tehrani Z et al. Binding and neutralization antibody titers after a single vaccine dose in
400 health care workers previously infected with SARS-CoV-2. *JAMA*. 2021;325(14):1467-1469. doi:
401 10.1001/jama.2021.3341.
- 402 30. Krammer F, Srivastava K, Alshammery H et al. Antibody responses in seropositive persons after a single dose of
403 SARS-CoV-2 mRNA vaccine. *N Engl J Med*. 2021;384(14):1372-1374. doi: 10.1056/NEJMc2101667.
- 404 31. Wajnberg A, Amanat F, Firpo A et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
405 *Science*. 2020;370:1227–1230. doi: 10.1126/science.abd7728.
- 406 32. Amanat F, Thapa M, Lei T et al. SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to
407 NTD, RBD, and S2. *Cell*. 2021;184(15):3936-3948.e10. doi: 10.1016/j.cell.2021.06.005.
- 408 33. Liu STH, Lin HM, Baine I et al. Convalescent plasma treatment of severe COVID-19: a propensity score-
409 matched control study. *Nat. Med*. 2020;26:1708–1713. doi: 10.1038/s41591-020-1088-9.
- 410 34. Amanat F, Stadlbauer D, Strohmeyer S et al. A serological assay to detect SARS-CoV-2 seroconversion in
411 humans. *Nat. Med*. 2020;26: 1033–1036. doi: 10.1038/s41591-020-0913-5.
- 412 35. Dan JM, Mateus J, Kato Y et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after
413 infection. *Science*. 2021;371(6529):eabf4063. doi: 10.1126/science.abf4063.
- 414 36. Zitt E, Davidovic T, Schimpf J et al. The safety and immunogenicity of the mRNA-BNT162b2 SARS-CoV-2
415 vaccine in hemodialysis patients. *Front Immunol*. 2021;12:704773. doi: 10.3389/fimmu.2021.704773.
- 416 37. Sauré D, O’Ryan M, Torres JP et al. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2
417 COVID-19 vaccines in Chile: a sentinel surveillance study. *Lancet Infect Dis*. 2022;22(1):56-63. doi:
418 10.1016/S1473-3099(21)00479-5.
- 419 38. Chukwu CA, Mahmood K, Elmakki S et al. Evaluating the antibody response to SARS-COV-2 vaccination
420 amongst kidney transplant recipients at a single nephrology centre. *PLoS One*. 2022;17(3):e0265130. doi:
421 10.1371/journal.pone.0265130.
- 422 39. Accorsi EK, Britton A, Fleming-Dutra KE et al. Association between 3 Doses of mRNA COVID-19 vaccine and
423 symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. *JAMA*. 2022;327(7):639-651. doi:
424 10.1001/jama.2022.0470.
- 425 40. Rottenberg Y, Grinshpun A, Ben-Dov IZ et al. Assessment of response to a third dose of the SARS-CoV-2
426 BNT162b2 mRNA vaccine in patients with solid tumors undergoing active treatment. *JAMA Oncol*. 2022;8(2):300-
427 301. doi: 10.1001/jamaoncol.2021.6764.
- 428 41. Weinreich DM, Sivapalasingam S, Norton T et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients
429 with Covid-19. *N Engl J Med*. 2021;384(3):238-251. doi: 10.1056/NEJMoa2035002.
- 430 42. O’Brien MP, Forleo-Neto E, Musser BJ et al. Subcutaneous REGEN-COV antibody combination to prevent
431 Covid-19. *N Engl J Med*. 2021;385(13):1184-1195. doi: 10.1056/NEJMoa2109682.
- 432 43. Weinreich DM, Sivapalasingam S, Norton T et al. REGEN-COV antibody combination and outcomes in
433 outpatients with Covid-19. *N Engl J Med*. 2021;385(23):e81. doi: 10.1056/NEJMoa2108163.
- 434 44. Tulchinsky TH. Maurice Hilleman: Creator of vaccines that changed the world. *Case Studies in Public Health*.
435 2018;443–470. doi:10.1016/B978-0-12-804571-8.00003-2.
- 436 45. Mast EE, Weinbaum CM, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of
437 hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization
438 Practices (ACIP) Part II: immunization of adults. *MMWR Recomm Rep*. 2006;55(RR-16):1–33. quiz CE1-4.
- 439 46. Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine in medical staff of hemodialysis units: efficacy
440 and subtype cross-protection. *N Engl J Med*. 1982;307(24):1481-6. doi: 10.1056/NEJM198212093072403.
- 441 47. Roome AJ, Walsh SJ, Cartter ML et al. Hepatitis B vaccine responsiveness in Connecticut public safety
442 personnel. *JAMA*. 1993;270(24):2931-4.
- 443 48. Van Oekelen O, Gleason CR, Agte S et al. Highly variable SARS-CoV-2 spike antibody responses to two doses
444 of COVID-19 RNA vaccination in patients with multiple myeloma. *Cancer Cell*. 2021;39:1028–1030 (2021). doi:
445 10.1016/j.ccell.2021.06.014.
- 446 49. Ollila TA, Lu S, Masel R et al. Antibody response to COVID-19 vaccination in adults with hematologic

- 447 malignant disease. *JAMA Oncol.* 2021;7:1714–1716. doi: 10.1001/jamaoncol.2021.4381.
- 448 50. Greenberger LM, Saltzman LA, Senefeld JW et al. Antibody response to SARS-CoV-2 vaccines in patients with
449 hematologic malignancies. *Cancer Cell.* 2021;39:1031–1033. doi: 10.1016/j.ccell.2021.07.012.
- 450 51. Massarweh A, Eliakim-Raz N, Stemmer A et al. Evaluation of seropositivity following BNT162b2 messenger
451 RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. *JAMA Oncol.* 2021;7(8):1133–1140.
452 doi: 10.1001/jamaoncol.2021.2155.
- 453 52. Obeid M, Suffiotti M, Pellaton C et al. Humoral responses against variants of concern by COVID-19 mRNA
454 vaccines in immunocompromised patients. *JAMA Oncol.* 2022; e220446. doi: 10.1001/jamaoncol.2022.0446.
- 455 53. Maneikis K, Šablaukas K, Ringelevičiūtė U et al. Immunogenicity of the BNT162b2 COVID-19 mRNA
456 vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national
457 prospective cohort study. *Lancet Haematol.* 2021;8(8):e583–e592. doi: 10.1016/S2352-3026(21)00169-1.
- 458 54. Kamar N, Abravanel F, Marion O et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant
459 recipients. *N Engl J Med.* 2021;385(7):661–662. doi: 10.1056/NEJMc2108861.
- 460 55. Boyarsky BJ, Werbel WA, Avery RK et al. Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in
461 solid organ transplant recipients. *JAMA.* 2021;325(21):2204–2206. doi: 10.1001/jama.2021.7489.
- 462 56. Centers for Disease Control and Prevention. Using antibody tests for COVID-19.
463 <https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests.html>
- 464 57. Lustig Y, Nemet I, Kliker L et al. Neutralizing response against variants after SARS-CoV-2 infection and one
465 dose of BNT162b2. *N Engl J Med.* 2021 Jun 24;384(25):2453–2454. doi: 10.1056/NEJMc2104036.
- 466 58. Garcia-Beltran WF, St Denis KJ, Hoelzemer A et al. mRNA-based COVID-19 vaccine boosters induce
467 neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell.* 2022;185(3):457–466.e4. doi:
468 10.1016/j.cell.2021.12.033.
- 469 59. Collie S, Champion J, Moultrie H et al. Effectiveness of BNT162b2 vaccine against Omicron variant in South
470 Africa. *N Engl J Med.* 2022;386(5):494–496. doi: 10.1056/NEJMc2119270.
- 471 60. Andrews N, Stowe J, Kirsebom F et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant.
472 *N Engl J Med.* 2022;NEJMoa2119451. doi: 10.1056/NEJMoa2119451.
- 473 61. Madhi SA, Kwatra G, Myers JE et al. Population immunity and Covid-19 severity with Omicron variant in
474 South Africa. *N Engl J Med.* 2022 Feb 23;NEJMoa2119658. doi: 10.1056/NEJMoa2119658. Online ahead of print
- 475 62. Lopez Bernal J, Andrews N, Gower C et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta)
476 variant. *N Engl J Med.* 2021;385(7):585–594. doi: 10.1056/NEJMoa2108891.
- 477 63. Hall VG, Ferreira VH, Ku T et al. Randomized trial of a third dose of mRNA-1273 vaccine in transplant
478 recipients. *N Engl J Med.* 2021;385(13):1244–1246. doi: 10.1056/NEJMc2111462.
- 479 64. Benotmane I, Gautier G, Perrin P et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2
480 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. *JAMA.* 2021;326(11):1063–5.
481 doi: 10.1001/jama.2021.12339.
- 482 65. Kamar N, Abravanel F, Marion O et al. Assessment of 4 Doses of SARS-CoV-2 messenger RNA-based vaccine
483 in recipients of a solid organ transplant. *JAMA Netw Open.* 2021;4(11):e2136030. doi:
484 10.1001/jamanetworkopen.2021.36030.
- 485 66. Sfeir MM, Snayd M. Serologic testing for hepatitis B. *JAMA.* 2021 Dec 21;326(23):2423–2424. doi:
486 10.1001/jama.2021.19803.
- 487 67. Zheng H, Zhang GM, Chan PL et al. Compliance among infants exposed to hepatitis B virus in a post-
488 vaccination serological testing program in four provinces in China. *Infect Dis Poverty.* 2019 ;8(1):57. doi:
489 10.1186/s40249-019-0568-y.
- 490 68. Trevisan A, Frasson C, De Nuzzo D et al. Significance of anti-HB levels below 10 IU/L after vaccination against
491 hepatitis B in infancy or adolescence: an update in relation to sex. *Hum Vaccin Immunother.* 2020;16(2):460–464.
492 doi: 10.1080/21645515.2019.1656483.
- 493 69. Le MH, Yeo YH, So S et al. Prevalence of hepatitis B vaccination coverage and serologic evidence of immunity
494 among US-born children and adolescents from 1999 to 2016. *JAMA Netw Open.* 2020;3(11):e2022388. doi:
495 10.1001/jamanetworkopen.2020.22388.
- 496 70. Wood RC, MacDonald KL, White KE et al. Risk factors for lack of detectable antibody following hepatitis B
497 vaccination of Minnesota health care workers. *JAMA.* 1993;270(24):2935–9.
- 498 71. Wen W, Chen C, Tang J et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir,
499 flvoxamine and Paxlovid) for COVID-19: a meta-analysis. *Ann Med.* 2022 Dec;54(1):516–523. doi:
500 10.1080/07853890.2022.2034936.
- 501 72. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports.
502 *BMJ.* 2021;375:n2713. doi: 10.1136/bmj.n2713.

503 73. Gandhi RT, Malani PN, Del Rio C. COVID-19 therapeutics for nonhospitalized patients. JAMA.
504 2022 ;327(7):617-618. doi: 10.1001/jama.2022.0335.

505 74. Baker MA, Rhee C, Tucker R et al. Rapid control of hospital-based SARS-CoV-2 omicron clusters through daily
506 testing and universal use of N95 respirators. Clin Infect Dis. 2022 Feb 7:ciac113. doi: 10.1093/cid/ciac113.

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545


546

547

548

549

550 **Figures**
551
552



553
554
555
556 **Fig. 1. Immune characteristics of 627 individuals.** (A) Naïve cellular immune parameters of the 627 cases who
557 received physical examinations. These naïve immune cells wane significantly, while the natural killer (NK) cell
558 counts increase significantly in the elderly people. ALC = absolute lymphocyte count. (B) The anti-spike IgG levels
559 after complete vaccination of the 627 cases. The quantitative level of the anti-spike IgG was significantly lower in
560 the ≥60 yr group (median 307.2, IQRs 118.2–417.3 BAU/mL) than that in the 18–59 yr group (median 416.8, IQRs
561 355.7–479.2 BAU/mL, $P < 0.001$). Mean and standard error of the mean (SEM) were shown. (C) The vaccine-
562 induced responses using the 4-fold increase after complete vaccination of the 627 cases. There were 7.5% non-
563 responders (fold-index < 4) among the 18–59 yr group and 11.7% in the ≥60 yr group. The reference ranges (1–99
564 percentile) for responders (fold-index ≥ 4) were 43.9–592.0 BAU/mL in combination of the 18–59 yr group and the
565 ≥60 yr group. A cutoff line at fold-index 4 was showed. (D) In the responder group (fold-index ≥ 4), intervals for 1–
566 99 percentile were 131.8–592.3 BAU/mL in the 18–59 yr group, and 29.7–500.9 BAU/mL in the ≥60 yr group,
567 respectively. Mean and standard error of the mean (SEM) were shown.

568
569
570
571

572 **Tables**

573

574 **Table 1. Immune characteristics of individuals before and after vaccination**

575

Characteristics	18–59 yr group	≥60 yr group	<i>P</i> value
Total number of cases	361	266	
Sex (%)			
Male	183 (50.7)	136 (51.1)	
Female	178 (49.3)	130 (48.9)	
Mean age (SD) in yr	45 (9)	67 (6)	
Naïve immune cells, median (IQRs)			
Lymphocytes (/mm³)	1,476 (1,168–1,875)	1,281 (1,023–1,520)	<0.001
CD4 cells (/mm³)	851 (677–1,151)	747 (562–955)	<0.001
CD8 cells (/mm³)	490 (357–632)	418 (288–544)	<0.001
B cells (/mm³)	256 (179–367)	204 (138–303)	<0.001
Natural killer cells (/mm³)	193 (141–287)	234 (162–355)	<0.001
Anti-spike IgG			
Seropositivity % (no.)	99.7 (360/361)	98.9 (263/266)	
Median (IQRs) (BAU/mL)	416.8 (355.7–479.2)	307.2 (118.2–417.3)	<0.001

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602 **Table 2. Characteristics of seroconversion after the complete dose of inactivated SARS-CoV-2 vaccines**

Characteristics	18–59 yr group			≥60 yr group		
	Fold-index <4	Fold-index ≥4	<i>P</i> value	Fold-index <4	Fold-index ≥4	<i>P</i> value
Total number of cases	361			266		
Anti-spike IgG BAU/mL (2.5–97.5 percentile)	88.6–576.2			27.7–491.0		
Fold-index % (no.)*	7.5 (27/361)	92.5 (334/361)		11.7 (31/266)	88.3 (235/266)	
Anti-spike IgG BAU/mL						
Median (IQRs)	115.8 (88.6–167.8)	420.8 (369.9–480.6)	<0.0001	63.9 (35.1–106.9)	346.0 (160.4–424.7)	<0.0001
2.5–97.5 percentile	18.3–266.3	200.7–576.5		5.4–317.8	46.6–491.1	
Naïve immune cells (mm³)						
Lymphocytes, mean (95% CI)	1,130 (1,007–1,252)	1,578 (1,524–1,633)	<0.0001	1,015 (888–1,143)	1,344 (1,291–1,397)	<0.0001
CD4 cells, mean (95% CI)	631 (555–708)	942 (905–979)	<0.0001	563 (494–631)	818 (777–858)	<0.0001
CD8 cells, mean (95% CI)	414 (349–479)	532 (508–557)	0.0081	394 (310–478)	444 (420–468)	0.1744
B cells, mean (95% CI)	119 (72–166)	306 (289–323)	<0.0001	74 (60–88)	248 (231–266)	<0.0001
NK cells, mean (95% CI)	192 (151–233)	235 (220–251)	0.1241	281 (225–337)	286 (261–311)	0.8902

603 *Post-vaccination testing was done at intervals of 14 to 90 days after the second vaccine dose. The reference ranges were defined as the 2.5–97.5
604 percentile in the study.